Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
208.9 USD | +3.18% | +7.47% | -19.27% |
04-26 | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
04-25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
ETFs positioned on Biogen Inc.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.30% | 1 M€ | -5.79% | - | |
3.92% | 0 M€ | 0.00% | - | |
3.75% | 0 M€ | 0.00% | - | |
2.39% | 14,021 M€ | +4.56% | ||
2.28% | 4 M€ | +20.15% | ||
1.91% | 6 M€ | +16.84% | - | |
1.78% | 115 M€ | +5.90% | - | |
1.69% | 2 M€ | +6.77% | ||
1.60% | 8 M€ | +2.44% | ||
1.33% | 1,182 M€ | +1.06% | ||
1.30% | 9 M€ | -4.31% | - | |
1.00% | 16 M€ | -8.49% | ||
0.99% | 18 M€ | +3.79% | - | |
0.97% | 13 M€ | -.--% | - | |
0.97% | 3 M€ | +7.32% | - | |
0.97% | 1 M€ | +11.94% | - | |
0.94% | 204 M€ | +10.54% | ||
0.65% | 2 M€ | -25.75% | ||
0.64% | 8 M€ | +5.48% | - | |
0.48% | 4,592 M€ | +11.18% | ||
0.44% | 1 M€ | +16.32% | ||
0.43% | 26 M€ | +16.85% | - | |
0.38% | 2 M€ | +20.44% | - | |
0.38% | 22 M€ | 0.00% | - | |
0.37% | 5 M€ | -72.95% | - | |
0.37% | 9 M€ | -.--% | - | |
0.36% | 3 M€ | 0.00% | - | |
0.29% | 92 M€ | +0.06% | - | |
0.29% | 469 M€ | -2.05% | - | |
0.29% | 3,859 M€ | +18.82% | - | |
0.21% | 8 M€ | +3.41% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.27% | 30.42B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- BIIB Stock
- Funds and ETFs Biogen Inc.